Selection of 3 products from
£0.59 to £1.79
Benefortin tablets contains benazapril which is one of the best drugs for treating heart failure in dogs or kidney failure in cats. It has the advantage over other formulations of being exceptionally palatable, so the tablets are much easier to give. This means that dogs and cats are more likely to receive the full benefit of the medication bought for them. Benazapril is known to be bitter tasting, but these tablets remain palatable even when crushed into food. Other tablets with the same ingredient are not swallowed as readily by animal patients and can be "spat out" without owners being aware. Benefortin can be given alone, or combined with other medications and special diets to best control the effects of the illness being treated.
All prices include VAT where applicable.
Brownish, oval, divisible tablet scored on both sides. The tablets can be divided into equal halves.
Each 2.5 mg tablet contains: Active substance Benazepril hydrochloride: 2.5 mg (equivalent to Benazepril 2.30 mg).
Each 5 mg tablet contains: Active substance Benazepril hydrochloride: 5.0 mg (equivalent to Benazepril 4.60 mg).
Each 20 mg tablet contains: Active substance Benazepril hydrochloride: 20.0 mg(equivalent to Benazepril 18.4 mg).
Dogs: Treatment of congestive heart failure.
Cats: Reduction of proteinuria associated with chronic kidney disease. (Benefortin Flavour 2.5 mg and 5 mg tablets for cats and dogs only).
The veterinary medicinal product should be given orally once daily, with or without food. The duration of treatment is unlimited. The tablets are flavoured and are taken voluntarily by most dogs and cats.
Cats: Tablets should be administered orally at a minimum dose of 0.5 mg (range 0.5 - 1.0) benazepril hydrochloride/kg body weight once daily according to the following dosing tables:
Dogs: Tablets should be administered orally at a minimum dose of 0.25 mg (range 0.25-0.5) benazepril hydrochloride/kg body weight once daily, according to the following table. The dose may be doubled, still administered once daily, to a minimum dose of 0.5 mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary surgeon, according to the dosing tables below:
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.
Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis. Do not use during pregnancy or lactation.
No evidence of renal toxicity of the veterinary medicinal product has been observed (in dogs or cats) during clinical trials, however, as is routine in cases of chronic kidney disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts during therapy. The efficacy and safety of benazepril has not been established in dogs and cats below 2.5 kg body weight. The chewable tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals.
In double-blind clinical trials in dogs with congestive heart failure, benazepril was well tolerated with an incidence of adverse reactions lower than observed in placebo treated dogs.
A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue. In cats and dogs with chronic kidney disease, benazepril may increase plasma creatinine concentrations at the start of therapy. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.
Benazepril may increase food consumption and body weight in cats. Emesis, anorexia, dehydration, lethargy and diarrhoea have been reported in rare occasions in cats.
Do not use during pregnancy or lactation. The safety of benazepril hydrochloride has not been established in breeding, pregnant or lactating dogs and cats. Benazepril reduced ovary/oviduct weights in cats when administered daily at 10 mg/kg body weight for 52 weeks. Embryotoxic effects (foetal urinary tract malformation) were seen in trials with laboratory animals (rats) at maternally non-toxic doses.
In dogs with congestive heart failure, benazepril hydrochloride has been given in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary medicinal products without demonstrable adverse interactions.
In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function. The combination of benazepril hydrochloride and other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or other medications with a hypotensive effect should be considered with care. Renal function and signs of hypotension (lethargy, weakness etc.) should be monitored closely and treated as necessary. Interactions with potassium-preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using benazepril in combination with a potassium sparing diuretic because of the risk of hyperkalaemia.
Benazepril reduced erythrocyte counts in normal cats when dosed at 10 mg/kg body weight once daily for 12 months and in normal dogs when dosed at 150 mg/kg body weight once daily for 12 months, but this effect was not observed at the recommended dose during clinical trials in cats or dogs.
Transient reversible hypotension may occur in cases of accidental overdose. Therapy should consist of intravenous infusion of warm isotonic saline.
Wash hands after use. In case of accidental oral ingestion, seek medical advice immediately and show the label or the package leaflet to the physician. Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.
Shelf-life of veterinary medicinal product as packaged for sale: 18 months.
Tablet halves should be used within 2 days.
Do not store above 25°C. Store in a dry place.
Each time an unused half tablet is stored, it should be returned to the open blister space and inserted back into the cardboard box and kept in a safe place out of the reach of children.
For animal treatment only - to be supplied only on a veterinary prescription.
Keep out of the sight and reach of children.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
2.5 mg presentation PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil with 14 tablets/blister. Cardboard box with 1 blister strip of 14 tablets (14 tablets) Cardboard box with 2 blister strips of 14 tablets (28 tablets) Cardboard box with 4 blister strips of 14 tablets (56 tablets) Cardboard box with 10 blister strips of 14 tablets (140 tablets) 5 mg presentation: PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil with 14 tablets/blister. Cardboard box with 1 blister strip of 14 tablets (14 tablets) Cardboard box with 2 blister strips of 14 tablets (28 tablets) Cardboard box with 4 blister strips of 14 tablets (56 tablets) Cardboard box with 10 blister strips of 14 tablets (140 tablets) 20 mg presentation PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil with 7 tablets/blister. Cardboard box with 1 blister strip of 7 tablets (7 tablets) Cardboard box with 2 blister strips of 7 tablets (14 tablets) Cardboard box with 4 blister strips of 7 tablets (28 tablets) Cardboard box with 10 blister strips of 7 tablets (70 tablets) Not all pack sizes may be marketed.
Benazepril hydrochloride is a prodrug hydrolysed in vivo to its active metabolite, benazeprilat. Benazeprilat is a highly potent and selective inhibitor of ACE, thus preventing the conversion of inactive angiotensin I to active angiotensin II and thereby also reducing synthesis of aldosterone. Therefore, it blocks effects mediated by angiotensin II and aldosterone, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes). Benazeprilat causes long-lasting inhibition of plasma ACE activity in dogs and cats, with more than 95% inhibition at peak effect and significant activity (>80% in dogs and >90% in cats) persisting 24 hours after dosing. Benazepril reduces the blood pressure and volume load on the heart in dogs with congestive heart failure. In cats with experimental renal insufficiency, benazepril normalized the elevated glomerular capillary pressure and reduced the systemic blood pressure. Reduction in glomerular hypertension may retard the progression of kidney disease by inhibition of further damage to the kidneys. Placebo controlled clinical field studies in cats with chronic kidney disease (CKD) have demonstrated that benazepril significantly reduced levels of urine protein and urine protein to creatinine ratio (UPC); this effect is probably mediated via reduced glomerular hypertension and beneficial effects on the glomerular basement membrane. No effect of benazepril hydrochloride on survival in cats with CKD has been shown, but benazepril hydrochloride increased the appetite of the cats, particularly in more advanced cases.
After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly (Tmax 0.5 hour in dogs and within 2 hours in cats) and decline quickly as the active substance is partially metabolised by liver enzymes to benazeprilat. The systemic bioavailability is incomplete (~13% in dogs) due to incomplete absorption (38% in dogs, <30% in cats) and first pass metabolism. In dogs, peak benazeprilat concentrations (Cmax of 37.6 ng/ml after a dose of 0.5 mg/kg benazepril hydrochloride) are achieved with a Tmax of 1.25 hours. In cats, peak benazeprilat concentrations (Cmax of 77.0 ng/ml after a dose of 0.5 mg/kg benazepril hydrochloride) are achieved with a Tmax of 2 hours. Benazeprilat concentrations decline biphasically: the initial fast phase (t1/2=1.7 hours in dogs and t1/2=2.4 hours in cats) represents elimination of free drug, while the terminal phase (t1/2=19 hours in dogs and t1/2=29 hours in cats) reflects the release of benazeprilat that was bound to ACE, mainly in the tissues. Benazepril and benazeprilat are extensively bound to plasma proteins (85-90%), and in tissues are found mainly in the liver and kidney. There is no significant difference in the pharmacokinetics of benazeprilat when benazepril hydrochloride is administered to fed or fasted dogs. Repeated administration of benazepril leads to slight bioaccumulation of benazeprilat (R= 1.47 in dogs and R=1.36 in cats with 0.5 mg/kg), steady state being achieved within a few days (4 days in dogs). Benazeprilat is excreted 54% via the biliary and 46% via the urinary route in dogs and 85% via the biliary and 15% via urinary route in cats. The clearance of benazeprilat is not affected in dogs or cats with impaired renal function and therefore no adjustment of dose of the veterinary medicinal product is required in either species in cases of renal insufficiency.
Lavet Pharmaceuticals Ltd., H-1161 Budapest, Ottó u. 14. Hungary
Vm 32823/4006 (2.5 mg), Vm 32823/4007 (5 mg), Vm 32823/4008 (20 mg).
Brownish, oval, divisible tablet scored on both sides. The tablets can be divided into equal halves.
Each 2.5 mg tablet contains: Active substance Benazepril hydrochloride: 2.5 mg (equivalent to Benazepril 2.30 mg).
Each 5 mg tablet contains: Active substance Benazepril hydrochloride: 5.0 mg (equivalent to Benazepril 4.60 mg).
Each 20 mg tablet contains: Active substance Benazepril hydrochloride: 20.0 mg(equivalent to Benazepril 18.4 mg).
Dogs: Treatment of congestive heart failure.
Cats: Reduction of proteinuria associated with chronic kidney disease. (Benefortin Flavour 2.5 mg and 5 mg tablets for cats and dogs only).
The veterinary medicinal product should be given orally once daily, with or without food. The duration of treatment is unlimited. The tablets are flavoured and are taken voluntarily by most dogs and cats.
Cats: Tablets should be administered orally at a minimum dose of 0.5 mg (range 0.5 - 1.0) benazepril hydrochloride/kg body weight once daily according to the following dosing tables:
Dogs: Tablets should be administered orally at a minimum dose of 0.25 mg (range 0.25-0.5) benazepril hydrochloride/kg body weight once daily, according to the following table. The dose may be doubled, still administered once daily, to a minimum dose of 0.5 mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary surgeon, according to the dosing tables below:
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.
Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis. Do not use during pregnancy or lactation.
No evidence of renal toxicity of the veterinary medicinal product has been observed (in dogs or cats) during clinical trials, however, as is routine in cases of chronic kidney disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts during therapy. The efficacy and safety of benazepril has not been established in dogs and cats below 2.5 kg body weight. The chewable tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals.
In double-blind clinical trials in dogs with congestive heart failure, benazepril was well tolerated with an incidence of adverse reactions lower than observed in placebo treated dogs.
A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue. In cats and dogs with chronic kidney disease, benazepril may increase plasma creatinine concentrations at the start of therapy. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.
Benazepril may increase food consumption and body weight in cats. Emesis, anorexia, dehydration, lethargy and diarrhoea have been reported in rare occasions in cats.
Do not use during pregnancy or lactation. The safety of benazepril hydrochloride has not been established in breeding, pregnant or lactating dogs and cats. Benazepril reduced ovary/oviduct weights in cats when administered daily at 10 mg/kg body weight for 52 weeks. Embryotoxic effects (foetal urinary tract malformation) were seen in trials with laboratory animals (rats) at maternally non-toxic doses.
In dogs with congestive heart failure, benazepril hydrochloride has been given in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary medicinal products without demonstrable adverse interactions.
In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function. The combination of benazepril hydrochloride and other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or other medications with a hypotensive effect should be considered with care. Renal function and signs of hypotension (lethargy, weakness etc.) should be monitored closely and treated as necessary. Interactions with potassium-preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using benazepril in combination with a potassium sparing diuretic because of the risk of hyperkalaemia.
Benazepril reduced erythrocyte counts in normal cats when dosed at 10 mg/kg body weight once daily for 12 months and in normal dogs when dosed at 150 mg/kg body weight once daily for 12 months, but this effect was not observed at the recommended dose during clinical trials in cats or dogs.
Transient reversible hypotension may occur in cases of accidental overdose. Therapy should consist of intravenous infusion of warm isotonic saline.
Wash hands after use. In case of accidental oral ingestion, seek medical advice immediately and show the label or the package leaflet to the physician. Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.
Shelf-life of veterinary medicinal product as packaged for sale: 18 months.
Tablet halves should be used within 2 days.
Do not store above 25°C. Store in a dry place.
Each time an unused half tablet is stored, it should be returned to the open blister space and inserted back into the cardboard box and kept in a safe place out of the reach of children.
For animal treatment only - to be supplied only on a veterinary prescription.
Keep out of the sight and reach of children.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
2.5 mg presentation PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil with 14 tablets/blister. Cardboard box with 1 blister strip of 14 tablets (14 tablets) Cardboard box with 2 blister strips of 14 tablets (28 tablets) Cardboard box with 4 blister strips of 14 tablets (56 tablets) Cardboard box with 10 blister strips of 14 tablets (140 tablets) 5 mg presentation: PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil with 14 tablets/blister. Cardboard box with 1 blister strip of 14 tablets (14 tablets) Cardboard box with 2 blister strips of 14 tablets (28 tablets) Cardboard box with 4 blister strips of 14 tablets (56 tablets) Cardboard box with 10 blister strips of 14 tablets (140 tablets) 20 mg presentation PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil with 7 tablets/blister. Cardboard box with 1 blister strip of 7 tablets (7 tablets) Cardboard box with 2 blister strips of 7 tablets (14 tablets) Cardboard box with 4 blister strips of 7 tablets (28 tablets) Cardboard box with 10 blister strips of 7 tablets (70 tablets) Not all pack sizes may be marketed.
Benazepril hydrochloride is a prodrug hydrolysed in vivo to its active metabolite, benazeprilat. Benazeprilat is a highly potent and selective inhibitor of ACE, thus preventing the conversion of inactive angiotensin I to active angiotensin II and thereby also reducing synthesis of aldosterone. Therefore, it blocks effects mediated by angiotensin II and aldosterone, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes). Benazeprilat causes long-lasting inhibition of plasma ACE activity in dogs and cats, with more than 95% inhibition at peak effect and significant activity (>80% in dogs and >90% in cats) persisting 24 hours after dosing. Benazepril reduces the blood pressure and volume load on the heart in dogs with congestive heart failure. In cats with experimental renal insufficiency, benazepril normalized the elevated glomerular capillary pressure and reduced the systemic blood pressure. Reduction in glomerular hypertension may retard the progression of kidney disease by inhibition of further damage to the kidneys. Placebo controlled clinical field studies in cats with chronic kidney disease (CKD) have demonstrated that benazepril significantly reduced levels of urine protein and urine protein to creatinine ratio (UPC); this effect is probably mediated via reduced glomerular hypertension and beneficial effects on the glomerular basement membrane. No effect of benazepril hydrochloride on survival in cats with CKD has been shown, but benazepril hydrochloride increased the appetite of the cats, particularly in more advanced cases.
After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly (Tmax 0.5 hour in dogs and within 2 hours in cats) and decline quickly as the active substance is partially metabolised by liver enzymes to benazeprilat. The systemic bioavailability is incomplete (~13% in dogs) due to incomplete absorption (38% in dogs, <30% in cats) and first pass metabolism. In dogs, peak benazeprilat concentrations (Cmax of 37.6 ng/ml after a dose of 0.5 mg/kg benazepril hydrochloride) are achieved with a Tmax of 1.25 hours. In cats, peak benazeprilat concentrations (Cmax of 77.0 ng/ml after a dose of 0.5 mg/kg benazepril hydrochloride) are achieved with a Tmax of 2 hours. Benazeprilat concentrations decline biphasically: the initial fast phase (t1/2=1.7 hours in dogs and t1/2=2.4 hours in cats) represents elimination of free drug, while the terminal phase (t1/2=19 hours in dogs and t1/2=29 hours in cats) reflects the release of benazeprilat that was bound to ACE, mainly in the tissues. Benazepril and benazeprilat are extensively bound to plasma proteins (85-90%), and in tissues are found mainly in the liver and kidney. There is no significant difference in the pharmacokinetics of benazeprilat when benazepril hydrochloride is administered to fed or fasted dogs. Repeated administration of benazepril leads to slight bioaccumulation of benazeprilat (R= 1.47 in dogs and R=1.36 in cats with 0.5 mg/kg), steady state being achieved within a few days (4 days in dogs). Benazeprilat is excreted 54% via the biliary and 46% via the urinary route in dogs and 85% via the biliary and 15% via urinary route in cats. The clearance of benazeprilat is not affected in dogs or cats with impaired renal function and therefore no adjustment of dose of the veterinary medicinal product is required in either species in cases of renal insufficiency.
Lavet Pharmaceuticals Ltd., H-1161 Budapest, Ottó u. 14. Hungary
Vm 32823/4006 (2.5 mg), Vm 32823/4007 (5 mg), Vm 32823/4008 (20 mg).
Brownish, oval, divisible tablet scored on both sides. The tablets can be divided into equal halves.
Each 2.5 mg tablet contains: Active substance Benazepril hydrochloride: 2.5 mg (equivalent to Benazepril 2.30 mg).
Each 5 mg tablet contains: Active substance Benazepril hydrochloride: 5.0 mg (equivalent to Benazepril 4.60 mg).
Each 20 mg tablet contains: Active substance Benazepril hydrochloride: 20.0 mg(equivalent to Benazepril 18.4 mg).
Dogs: Treatment of congestive heart failure.
Cats: Reduction of proteinuria associated with chronic kidney disease. (Benefortin Flavour 2.5 mg and 5 mg tablets for cats and dogs only).
The veterinary medicinal product should be given orally once daily, with or without food. The duration of treatment is unlimited. The tablets are flavoured and are taken voluntarily by most dogs and cats.
Cats: Tablets should be administered orally at a minimum dose of 0.5 mg (range 0.5 - 1.0) benazepril hydrochloride/kg body weight once daily according to the following dosing tables:
Dogs: Tablets should be administered orally at a minimum dose of 0.25 mg (range 0.25-0.5) benazepril hydrochloride/kg body weight once daily, according to the following table. The dose may be doubled, still administered once daily, to a minimum dose of 0.5 mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary surgeon, according to the dosing tables below:
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.
Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis. Do not use during pregnancy or lactation.
No evidence of renal toxicity of the veterinary medicinal product has been observed (in dogs or cats) during clinical trials, however, as is routine in cases of chronic kidney disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts during therapy. The efficacy and safety of benazepril has not been established in dogs and cats below 2.5 kg body weight. The chewable tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals.
In double-blind clinical trials in dogs with congestive heart failure, benazepril was well tolerated with an incidence of adverse reactions lower than observed in placebo treated dogs.
A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue. In cats and dogs with chronic kidney disease, benazepril may increase plasma creatinine concentrations at the start of therapy. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.
Benazepril may increase food consumption and body weight in cats. Emesis, anorexia, dehydration, lethargy and diarrhoea have been reported in rare occasions in cats.
Do not use during pregnancy or lactation. The safety of benazepril hydrochloride has not been established in breeding, pregnant or lactating dogs and cats. Benazepril reduced ovary/oviduct weights in cats when administered daily at 10 mg/kg body weight for 52 weeks. Embryotoxic effects (foetal urinary tract malformation) were seen in trials with laboratory animals (rats) at maternally non-toxic doses.
In dogs with congestive heart failure, benazepril hydrochloride has been given in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary medicinal products without demonstrable adverse interactions.
In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function. The combination of benazepril hydrochloride and other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or other medications with a hypotensive effect should be considered with care. Renal function and signs of hypotension (lethargy, weakness etc.) should be monitored closely and treated as necessary. Interactions with potassium-preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using benazepril in combination with a potassium sparing diuretic because of the risk of hyperkalaemia.
Benazepril reduced erythrocyte counts in normal cats when dosed at 10 mg/kg body weight once daily for 12 months and in normal dogs when dosed at 150 mg/kg body weight once daily for 12 months, but this effect was not observed at the recommended dose during clinical trials in cats or dogs.
Transient reversible hypotension may occur in cases of accidental overdose. Therapy should consist of intravenous infusion of warm isotonic saline.
Wash hands after use. In case of accidental oral ingestion, seek medical advice immediately and show the label or the package leaflet to the physician. Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.
Shelf-life of veterinary medicinal product as packaged for sale: 18 months.
Tablet halves should be used within 2 days.
Do not store above 25°C. Store in a dry place.
Each time an unused half tablet is stored, it should be returned to the open blister space and inserted back into the cardboard box and kept in a safe place out of the reach of children.
For animal treatment only - to be supplied only on a veterinary prescription.
Keep out of the sight and reach of children.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
2.5 mg presentation PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil with 14 tablets/blister. Cardboard box with 1 blister strip of 14 tablets (14 tablets) Cardboard box with 2 blister strips of 14 tablets (28 tablets) Cardboard box with 4 blister strips of 14 tablets (56 tablets) Cardboard box with 10 blister strips of 14 tablets (140 tablets) 5 mg presentation: PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil with 14 tablets/blister. Cardboard box with 1 blister strip of 14 tablets (14 tablets) Cardboard box with 2 blister strips of 14 tablets (28 tablets) Cardboard box with 4 blister strips of 14 tablets (56 tablets) Cardboard box with 10 blister strips of 14 tablets (140 tablets) 20 mg presentation PVC/Aluminium/Polyamide blister-forming laminate with aluminium lidding foil with 7 tablets/blister. Cardboard box with 1 blister strip of 7 tablets (7 tablets) Cardboard box with 2 blister strips of 7 tablets (14 tablets) Cardboard box with 4 blister strips of 7 tablets (28 tablets) Cardboard box with 10 blister strips of 7 tablets (70 tablets) Not all pack sizes may be marketed.
Benazepril hydrochloride is a prodrug hydrolysed in vivo to its active metabolite, benazeprilat. Benazeprilat is a highly potent and selective inhibitor of ACE, thus preventing the conversion of inactive angiotensin I to active angiotensin II and thereby also reducing synthesis of aldosterone. Therefore, it blocks effects mediated by angiotensin II and aldosterone, including vasoconstriction of both arteries and veins, retention of sodium and water by the kidney and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes). Benazeprilat causes long-lasting inhibition of plasma ACE activity in dogs and cats, with more than 95% inhibition at peak effect and significant activity (>80% in dogs and >90% in cats) persisting 24 hours after dosing. Benazepril reduces the blood pressure and volume load on the heart in dogs with congestive heart failure. In cats with experimental renal insufficiency, benazepril normalized the elevated glomerular capillary pressure and reduced the systemic blood pressure. Reduction in glomerular hypertension may retard the progression of kidney disease by inhibition of further damage to the kidneys. Placebo controlled clinical field studies in cats with chronic kidney disease (CKD) have demonstrated that benazepril significantly reduced levels of urine protein and urine protein to creatinine ratio (UPC); this effect is probably mediated via reduced glomerular hypertension and beneficial effects on the glomerular basement membrane. No effect of benazepril hydrochloride on survival in cats with CKD has been shown, but benazepril hydrochloride increased the appetite of the cats, particularly in more advanced cases.
After oral administration of benazepril hydrochloride, peak levels of benazepril are attained rapidly (Tmax 0.5 hour in dogs and within 2 hours in cats) and decline quickly as the active substance is partially metabolised by liver enzymes to benazeprilat. The systemic bioavailability is incomplete (~13% in dogs) due to incomplete absorption (38% in dogs, <30% in cats) and first pass metabolism. In dogs, peak benazeprilat concentrations (Cmax of 37.6 ng/ml after a dose of 0.5 mg/kg benazepril hydrochloride) are achieved with a Tmax of 1.25 hours. In cats, peak benazeprilat concentrations (Cmax of 77.0 ng/ml after a dose of 0.5 mg/kg benazepril hydrochloride) are achieved with a Tmax of 2 hours. Benazeprilat concentrations decline biphasically: the initial fast phase (t1/2=1.7 hours in dogs and t1/2=2.4 hours in cats) represents elimination of free drug, while the terminal phase (t1/2=19 hours in dogs and t1/2=29 hours in cats) reflects the release of benazeprilat that was bound to ACE, mainly in the tissues. Benazepril and benazeprilat are extensively bound to plasma proteins (85-90%), and in tissues are found mainly in the liver and kidney. There is no significant difference in the pharmacokinetics of benazeprilat when benazepril hydrochloride is administered to fed or fasted dogs. Repeated administration of benazepril leads to slight bioaccumulation of benazeprilat (R= 1.47 in dogs and R=1.36 in cats with 0.5 mg/kg), steady state being achieved within a few days (4 days in dogs). Benazeprilat is excreted 54% via the biliary and 46% via the urinary route in dogs and 85% via the biliary and 15% via urinary route in cats. The clearance of benazeprilat is not affected in dogs or cats with impaired renal function and therefore no adjustment of dose of the veterinary medicinal product is required in either species in cases of renal insufficiency.
Lavet Pharmaceuticals Ltd., H-1161 Budapest, Ottó u. 14. Hungary
Vm 32823/4006 (2.5 mg), Vm 32823/4007 (5 mg), Vm 32823/4008 (20 mg).
Under almost all products on our website is an Estimated dispatch time, check this for a delivery prediction specific to the item you are looking to purchase. These badges are updated live based on the stock levels we have and also those of our suppliers - so are usually very accurate, but cannot be guaranteed. In more general terms, we aim to dispatch all orders within 1 working day of receiving payment (and a prescription if required). If we cannot do so within 3 working days we will contact you by email.
For UK delivery, we charge the following:
| Order Total | Weight | Delivery |
| £0-£28.99 | Under 2kg | £2.99 |
| 2kg+ | £4.99 | |
| £29-£38.99 | Under 2kg | Free |
| 2kg+ | £4.99 | |
| £39+ | Under 2kg | Free |
| 2kg+ | Free |
Prices quoted are for delivery to all parts of mainland UK except certain Scottish postcodes (where the price is higher for items sent by courier. Delivery of food abroad (including Channel Islands, N. Ireland and other islands around the UK) is charged at a higher price and free delivery is not available. Temperature controlled products, such as Insulin, are also not always subject to the standard and/or free delivery options.
For full information on our delivery charges, including prices on heavy deliveries to Scotland and abroad, see our delivery information page.
We can deliver most items to all around the world, but prices do vary. The majority of light weight orders (less than 1.5kg) can be delivered for a flat rate of £10. For an accurate estimate of the delivery charge, please put the items you require in your basket and use the "Estimate Delivery" system on the shopping basket page (you only need to enter your country and postal/zip code) for a quick quote. For deliveries to the USA you may need to go to the checkout page and enter your full address to get a quote (as some services need your state in order to quote too). For more information on international deliveries, please see our delivery information page.
Due to restrictions aerosols can't be sent by Royal Mail. We appreciate your understanding.
Some products, such as insulin and frozen food, need to be delivered in insulated packaging to prevent them from getting too warm (or too cold) during transit from us to you. Purchasing any of these items in your order will result in a £1.99 charge being added to the total to cover the high cost of the insulated packaging materials. You only pay the £1.99 once per order, regardless of how many temperature controlled items you purchase in that order.
Please call us as soon as possible if you need to amend or cancel an order on 01582 842096. If your order has been processed for dispatch we will be unable to cancel or amend the order. You will however be able to return your product for a full refund*.
To return an item, you must contact us by phone or email to arrange this BEFORE posting any product back to us. We will explain the process at this stage for you.
*For full details on returns, see our terms and conditions page.
There are currently no questions for Benefortin for Dogs & Cats - be the first to ask one!
